基于虚毒瘀理论探讨铁死亡在肝癌发展中的作用
Exploring the Role of Ferroptosis in the Development of Liver Cancer Based on the Theory of Deficiency and Stasis
DOI: 10.12677/tcm.2025.147455, PDF,    科研立项经费支持
作者: 王馨莹, 刘文钒, 方得锦:广西中医药大学研究生院,广西 南宁;吕建林:广西中医药大学第一附属医院,广西 南宁
关键词: 肝癌虚毒瘀铁死亡扶正补虚解毒化瘀Liver Cancer Deficiency and Stasis Ferroptosis Correcting and Supplementing Deficiencies Detoxify and Dispel Stasis
摘要: 原发性肝癌为本虚标实之证,其核心病机可概括为“虚毒瘀”,以正虚为本,毒瘀二者互结于体内为标。因虚失养则致脏腑不固,邪毒可乘虚侵络,瘀阻气血;毒瘀互结后反耗正气,三者交织演化,故形成恶性循环。铁死亡是一种铁依赖性死亡程序,其发生与铁代谢紊乱、脂质过氧化物堆积以及抗氧化系统失衡等途径密切相关。而二者功能具有一定的相似性。铁死亡的产生过程是该理论的微观体现,所产生的铁代谢异常、脂质过氧化物的异常堆积与邪毒、瘀血所产生的过程相似。而在正虚上又可同抗氧化系统联系。因此,本文基于“虚毒瘀”理论,阐述该机制,并以扶正补虚、解毒化瘀为法,实现中医药可以多途径、多靶点调控铁死亡,对于肝癌的防治具有重要意义。
Abstract: Primary liver cancer is the evidence of deficiency and reality, and its core pathogenesis can be summarized as “deficiency and poison stasis”, which is based on positive and deficiency, and the two are combined with each other in the body. Due to the lack of nourishment, the viscera are not solid, and the evil poison can take advantage of the deficiency to invade the network, stasis and obstruct qi and blood; after the poison and stasis are combined, the positive qi is consumed, and the three are intertwined and evolved, so a vicious circle is formed. Ferroptosis is an iron-dependent death procedure that occurs in a pathway that is closely related to iron metabolism disorders, lipid peroxide accumulation, and imbalances in the antioxidant system. However, the functions of the two have certain similarities. The process of ferroptosis is a microscopic embodiment of this theory, and the abnormal iron metabolism and abnormal accumulation of lipid peroxides are similar to the processes produced by evil poison and blood stasis. In terms of positive and void, it can be linked to the antioxidant system. Therefore, based on the theory of “deficiency and poison stasis”, this paper expounds the mechanism, and realizes that traditional Chinese medicine can regulate ferroptosis in multiple ways and multiple targets by correcting and supplementing deficiencies and detoxify and dispel stasis, which is of great significance for the prevention and treatment of liver cancer.
文章引用:王馨莹, 刘文钒, 方得锦, 吕建林. 基于虚毒瘀理论探讨铁死亡在肝癌发展中的作用[J]. 中医学, 2025, 14(7): 3085-3093. https://doi.org/10.12677/tcm.2025.147455

参考文献

[1] 中华人民共和国国家卫生健康委员会医政司. 原发性肝癌诊疗指南(2024年版) [J]. 中华消化外科杂志, 2024, 23(4): 429-478.
[2] Tang, W., Sun, G., Ji, G., Feng, T., Zhang, Q., Cao, H., et al. (2023) Single-Cell RNA-Sequencing Atlas Reveals an FABP1-Dependent Immunosuppressive Environment in Hepatocellular Carcinoma. Journal for ImmunoTherapy of Cancer, 11, e007030. [Google Scholar] [CrossRef] [PubMed]
[3] Girardi, D.M., Sousa, L.P., Miranda, T.A., Haum, F.N.C., Pereira, G.C.B. and Pereira, A.A.L. (2023) Systemic Therapy for Advanced Hepatocellular Carcinoma: Current Stand and Perspectives. Cancers, 15, Article 1680. [Google Scholar] [CrossRef] [PubMed]
[4] 贾英杰. 试论癌瘤“正气内虚, 毒瘀并存”的病机观点[J]. 新中医, 2013, 45(6): 9-11.
[5] Tang, D., Chen, X., Kang, R. and Kroemer, G. (2020) Ferroptosis: Molecular Mechanisms and Health Implications. Cell Research, 31, 107-125. [Google Scholar] [CrossRef] [PubMed]
[6] 赵田禾, 孙东雷, 李欣洋, 等. 三氧化二砷对肝癌HepG2细胞铁死亡影响的研究[J]. 现代预防医学, 2019, 46(10): 1847-1851.
[7] 冯吉. 索拉非尼通过ACSL4介导肝癌细胞铁死亡的实验室和临床研究[D]: [硕士学位论文]. 南宁: 广西医科大学, 2020.
[8] 周灏, 刘丽丽, 施美, 等. 徐经世国医大师扶正祛邪治疗肝癌经验总结[J]. 中西医结合肝病杂志, 2022, 32(2): 106-109.
[9] Dixon, S.J., Lemberg, K.M., Lamprecht, M.R., Skouta, R., Zaitsev, E.M., Gleason, C.E., et al. (2012) Ferroptosis: An Iron-Dependent Form of Nonapoptotic Cell Death. Cell, 149, 1060-1072. [Google Scholar] [CrossRef] [PubMed]
[10] Liu, J., Kang, R. and Tang, D. (2021) Signaling Pathways and Defense Mechanisms of Ferroptosis. The FEBS Journal, 289, 7038-7050. [Google Scholar] [CrossRef] [PubMed]
[11] Capelletti, M.M., Manceau, H., Puy, H. and Peoc’h, K. (2020) Ferroptosis in Liver Diseases: An Overview. International Journal of Molecular Sciences, 21, Article 4908. [Google Scholar] [CrossRef] [PubMed]
[12] Thanan, R., Oikawa, S., Yongvanit, P., Hiraku, Y., Ma, N., Pinlaor, S., et al. (2012) Inflammation-Induced Protein Carbonylation Contributes to Poor Prognosis for Cholangiocarcinoma. Free Radical Biology and Medicine, 52, 1465-1472. [Google Scholar] [CrossRef] [PubMed]
[13] Mo, Y., Zou, Z. and Chen, E. (2023) Correction To: Targeting Ferroptosis in Hepatocellular Carcinoma. Hepatology International, 18, 1065-1065. [Google Scholar] [CrossRef] [PubMed]
[14] Jiang, M., Hu, R., Yu, R., Tang, Y. and Li, J. (2021) A Narrative Review of Mechanisms of Ferroptosis in Cancer: New Challenges and Opportunities. Annals of Translational Medicine, 9, 1599-1599. [Google Scholar] [CrossRef] [PubMed]
[15] 李开楊, 吴小梅, 罗梅, 等. 中药调控铁死亡治疗肝癌的研究进展[J/OL]. 沈阳药科大学学报: 1-12. 2025-06-11.[CrossRef
[16] Mancias, J.D., Wang, X., Gygi, S.P., Harper, J.W. and Kimmelman, A.C. (2014) Quantitative Proteomics Identifies NCOA4 as the Cargo Receptor Mediating Ferritinophagy. Nature, 509, 105-109. [Google Scholar] [CrossRef] [PubMed]
[17] Xiu, Z., Li, Y., Fang, J., Han, J., Li, S., Li, Y., et al. (2023) Inhibitory Effects of Esculetin on Liver Cancer through Triggering NCOA4 Pathway-Mediation Ferritinophagy in Vivo and in Vitro. Journal of Hepatocellular Carcinoma, 10, 611-629. [Google Scholar] [CrossRef] [PubMed]
[18] Xiu, Z., Zhu, Y., Han, J., Li, Y., Yang, X., Yang, G., et al. (2022) Caryophyllene Oxide Induces Ferritinophagy by Regulating the NCOA4/FTH1/LC3 Pathway in Hepatocellular Carcinoma. Frontiers in Pharmacology, 13, Article 930958. [Google Scholar] [CrossRef] [PubMed]
[19] 张了, 罗再, 黄陈. 脂质代谢介导的铁死亡在肿瘤进展中的作用及机制[J]. 中国生物化学与分子生物学报, 2025, 41(3): 353-363.
[20] 马佳乐, 梁欣奕, 张馨元, 等. 中药调控铁死亡防治胃癌及癌前病变的研究进展[J]. 中成药, 2025, 47(3): 839-846.
[21] Flores-Romero, H., Ros, U. and García-Sáez, A.J. (2020) A Lipid Perspective on Regulated Cell Death. International Review of Cell and Molecular Biology, 351, 197-236. [Google Scholar] [CrossRef] [PubMed]
[22] 黄彬彬, 周喜汉, 姜红梅, 等. 酰基辅酶A合成酶长链家族成员4介导铁死亡的机制及其在消化系统肿瘤中的研究进展[J]. 中国医药科学, 2025, 15(3): 44-47, 56.
[23] 赵培培, 周志刚, 杨媛媛, 等. 铁死亡诱导剂Erastin下调ACSL4抑制肝癌细胞体外增殖[J]. 南方医科大学学报, 2024, 44(11): 2131-2136.
[24] Louandre, C., Ezzoukhry, Z., Godin, C., Barbare, J., Mazière, J., Chauffert, B., et al. (2013) Iron‐Dependent Cell Death of Hepatocellular Carcinoma Cells Exposed to Sorafenib. International Journal of Cancer, 133, 1732-1742. [Google Scholar] [CrossRef] [PubMed]
[25] Feng, J., Lu, P., Zhu, G., Hooi, S.C., Wu, Y., Huang, X., et al. (2020) ACSL4 Is a Predictive Biomarker of Sorafenib Sensitivity in Hepatocellular Carcinoma. Acta Pharmacologica Sinica, 42, 160-170. [Google Scholar] [CrossRef] [PubMed]
[26] 陈意, 温海滨, 谭宁, 等. System Xc⁻在肿瘤中的调控研究进展[J]. 生命的化学, 2022, 42(7): 1344-1356.
[27] 郝定盈, 朱山飞, 毛本亮, 等. SLC7A11在肝癌中的研究进展[J]. 中国医药导报, 2024, 21(13): 191-193.
[28] Koppula, P., Zhuang, L. and Gan, B. (2021) Cystine Transporter SLC7A11/xCT in Cancer: Ferroptosis, Nutrient Dependency, and Cancer Therapy. Protein & Cell, 12, 599-620. [Google Scholar] [CrossRef] [PubMed]
[29] Yang, W.S., SriRamaratnam, R., Welsch, M.E., Shimada, K., Skouta, R., Viswanathan, V.S., et al. (2014) Regulation of Ferroptotic Cancer Cell Death by GPX4. Cell, 156, 317-331. [Google Scholar] [CrossRef] [PubMed]
[30] He, F., Zhang, P., Liu, J., Wang, R., Kaufman, R.J., Yaden, B.C., et al. (2023) ATF4 Suppresses Hepatocarcinogenesis by Inducing SLC7A11 (XCT) to Block Stress-Related Ferroptosis. Journal of Hepatology, 79, 362-377. [Google Scholar] [CrossRef] [PubMed]
[31] 梁欣奕, 马佳乐, 李慧臻, 等. 基于“脾-线粒体相关”理论探讨铁死亡与胃癌相关性[J]. 时珍国医国药, 2024, 35(2): 404-407.
[32] 朱泽锴, 佟晓雪, 邢成, 等. 基于“正虚毒泛”学说探讨中医药对肿瘤微环境的干预机制[J]. 环球中医药, 2025, 18(3): 531-536.
[33] 李飞燕, 王明刚, 毛德文, 等. 脂代谢重编程与原发性肝癌发生发展的关系[J]. 临床肝胆病杂志, 2024, 40(8): 1688-1692.
[34] 李晓晓, 马云飞, 李光达, 等. 恶性肿瘤血液高凝状态的发病机制及中西医治疗进展[J]. 世界中西医结合杂志, 2019, 14(11): 1619-1623.
[35] 廖春雨, 李清钰, 原玉柱, 等. 低氧诱导因子与铁代谢紊乱促肿瘤发展研究进展[J]. 中国药理学与毒理学杂志, 2022, 36(7): 529-535.
[36] Gao, D., Wu, Y., Zhan, Y., et al. (2025) Chronic Hypoxia Drives the Occurrence of Ferroptosis in Liver of Fat Greening (Hexagrammos Otakii) by Activating HIF-1α and Promoting Iron Production. Ecotoxicology and Environmental Safety, 285, Article ID: 117135. [Google Scholar] [CrossRef] [PubMed]
[37] Zhu, X., Yang, C., Yu, Q. and Han, L. (2025) Hypoxia-Inducible Factor-1α Promotes Ferroptosis by Inducing Ferritinophagy and Promoting Lactate Production in Yak Longissimus Thoracis Et Lumborum Postmortem. Meat Science, 220, Article ID: 109692. [Google Scholar] [CrossRef] [PubMed]
[38] 朱礼青, 王之心, 曹辉, 等. 黄芪多糖通过调控Wnt/β-Catenin信号通路促进肝癌细胞铁死亡并抑制细胞增殖[J]. 中国中西医结合外科杂志, 2025, 31(1): 123-127.
[39] 刘铭玥, 蔡岳松, 程颢颐, 等. 人参皂苷 CK 诱导人肝癌细胞铁死亡作用机制的研究[J]. 时珍国医国药, 2024, 35(3): 554-559.
[40] 杨晶. 基于GPX4通路探讨固本消积方对人肝癌HepG2细胞铁死亡的作用机制[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2022.
[41] 李可心. 基于p62/Keap1/NRF2通路探讨固本消积方干预人肝癌HepG2细胞铁死亡的作用机制[D]: [硕士学位论文]. 长沙: 湖南中医药大学, 2022.
[42] Li, Y., Zhang, J., Zhang, K., et al. (2022) Scutellaria barbata Inhibits Hepatocellular Carcinoma Tumorigenicity by Inducing Ferroptosis of Hepatocellular Carcinoma Cells. Frontiers in Oncology, 12, Article 693395. [Google Scholar] [CrossRef] [PubMed]
[43] 周季青, 黎华建, 曾煜豪, 等. 黄芩苷通过抑制ROS介导的PI3K/Akt/FoxO3a信号通路诱导HepG2细胞铁死亡[J]. 中国中药杂志, 2024, 49(5): 1327-1334.
[44] 张慧中, 倪健, 彭胡麟玥, 等. 重楼皂苷Ⅱ诱导肝癌HepG2细胞铁死亡作用机制[J]. 中国实验方剂学杂志, 2024, 30(17): 105-112.
[45] 李文婷, 张淇, 吴勉华, 等. 基于蛋白质组学探讨消癌解毒方调控Nrf2/HMOX1通路促进肝癌细胞铁死亡的作用机制[J]. 南京中医药大学学报, 2023, 39(12): 1179-1188.
[46] 蔡晓钧, 杨仁义, 王智槟, 等. 基于p53/SLC7A11/GPX4通路研究疏肝祛瘀解毒方诱导肝癌细胞铁死亡的作用机制[J]. 中国实验方剂学杂志, 2024, 30(8): 74-82.
[47] 李菁, 蔡晓钧, 杨仁义, 等. 疏肝祛瘀解毒方介导p53通路诱导铁死亡抑制裸鼠肝癌生长的研究[J]. 中国病理生理杂志, 2023, 39(12): 2176-2184.
[48] 刘金丽, 佟雷, 罗烨, 等. 隐丹参酮可能具有诱导人肝癌HepG2细胞铁死亡的作用[J]. 中国医学科学院学报, 2021, 43(3): 366-370.
[49] Lan, T., Wang, W., Zeng, X., Tong, Y., Mao, Z. and Wang, S. (2023) Saikosaponin a Triggers Cell Ferroptosis in Hepatocellular Carcinoma by Inducing Endoplasmic Reticulum Stress-Stimulated ATF3 Expression. Biochemical and Biophysical Research Communications, 674, 10-18. [Google Scholar] [CrossRef] [PubMed]
[50] 袁靖涛. 华泽兰有效部位EChLESs诱导凋亡及铁死亡抗肝癌作用研究[D]: [硕士学位论文]. 杭州: 浙江中医药大学, 2022.
[51] 吴瑶, 宋囡, 贾连群, 等. 化瘀祛痰方对载脂蛋白E基因敲除小鼠肝脏脂质过氧化及p53、GPX4、xCT表达的影响[J]. 中医杂志, 2020, 61(18): 1633-1638.
[52] 陈伟光, 何春雨, 文彬, 等. 鳖甲煎丸通过p62/Keap1/NRF2信号通路调控肝癌细胞铁死亡的作用机制研究[J]. 四川大学学报(医学版), 2025, 56(1): 51-58.